Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Anorexia and CYP2C19[original query] |
---|
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Investigational new drugs 2016 Dec . Kyriakopoulos Christos E, Braden Amy M, Kolesar Jill M, Eickhoff Jens C, Bailey Howard H, Heideman Jennifer, Liu Glenn, Wisinski Kari |
Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy. Epilepsy research 2017 1 130 7-12. Jogamoto Toshihiro, Yamamoto Yoshiaki, Fukuda Mitsumasa, Suzuki Yuka, Imai Katsumi, Takahashi Yukitoshi, Inoue Yushi, Ohtsuka Yo |
Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Medical oncology (Northwood, London, England) 2018 Mar 35 (4): 51. Igarashi Ryoma, Inoue Takamitsu, Fujiyama Nobuhiro, Tsuchiya Norihiko, Numakura Kazuyuki, Kagaya Hideaki, Saito Mitsuru, Narita Shintaro, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomono |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 20, 2024
- Content source: